Role of Newly-Approved HIV Antiretroviral Agents in Treatment-Experienced Patients (09HC08)

Home | Page 1 | Page 2 | Page 3 | Cases | References | Post-test

REFERENCES

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Washington, DC: US Department of Health and Human Services. December 1, 2007; 1-143. Accessed December 4, 2007. Available at:
   http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf.
   
   
2. Hammer SM, Saag MS, Schechte M, et al. Treatment for Adult HIV Infection: 2006 Recommendation of the International AIDS Society–US Panel. JAMA. 2006:296:827-843.
   
   
3. Bartlett JG. Modifying HIV Antiretroviral Therapy Regimens. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, 2007. Available at: http://wwww.uptodate.com.
   
   
4. Berger EA, Doms RW, Fenyo EM, et al. A New Classification of HIV-1. Nature. 1998:391:240.
   
   
5. Whitcomb J, Huang W, Fransen S, et al. Development and Characterization of a Novel Single-Cycle Recombinant Virus Assay to Determine Human Immunodeficiency Virus Type 1 Co-Receptor Tropism. Antimicrob Agents Chemother. 2007:1:566-575.
   
   
6. Lalezari J, et al. Efficacy and Safety of Maraviroc Plus Optimized Background Therapy in Viremic, ART-Experienced Patients Infected with CCR5-Tropic HIV-1: 24 Week Results of Phase 2b/3 Study in the U.S. and Canada. Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Feb. 25-28, 2007, Los Angeles, California. Abstract 104bLB.
   
   
7. Nelson M, et al. Efficacy and Safety of Maraviroc Plus Optimized Background Therapy in Viremic, ART-Experienced Patients Infected with CCR5-Tropic HIV-1 in Europe, Australia, and North America: 24 Week Results. Program and Abstracts of the 14th Conferenceon Retroviruses and Opportunistic Infections; Feb. 25-28, 2007, Los Angeles, California. Abstract 104aLB.
   
   
8. Selzentry (package insert). New York, NY: Pfizer; 2007. Available at http://www.pfizer.com
   
   
9. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Role of HIV Resistance Testing in Antiretroviral Drug Development. October 2007. Available at: http://www.fda.gov/cder/guidance/7688fnl.htm Accessed January 23, 2008.
   
   
10. Demarest J, Bonny T, et al. HIV-1 Coreceptor Tropism in Treatment Naïve and Experienced Subjects. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Oct. 30 - Nov. 2, 2004, Washington, D.C. Abstract H-1136.
    
    
11. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and Clinical Epidemiology of CXCR4 Using HIV-1 in a Large Population of Antiretroviral Naïve Individuals. J Infect Dis. 2005:192:466-474.
    
    
12. Moyle GJ, Wildfire A, Mandalia S,. et al. Epidemiology and Predictive Factors for Chemokine Receptors in HIV-1 infection. J Infect Dis. 2005. 191:866-872.
    
    
13. Melby T, Despirito M, Demasi R, Greenberg M, Graham N. HIV-1 Coreceptor use in Triple Class Treatment-Experienced Patients: Baseline Prevalence, Correlates, and Relationship to Enfuvirtide Response. J Infect Dis. 2006:194:238-246.
    
    
14. Wilkin T, Su Z, et al. HIV Type-1 Chemokine Coreceptor use Among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor. AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007:44:591-595.
    
    
15. U.S. Food and Drug Administration. Drugs Used in the Treatment of HIV Infection. Available at: http://www.fda.gov/oashi/aids/virals.html Accessed January 2, 2008.
    
    
16. Cooper D, Gatell J, et al. Results of BENCHMRK-1, A Phase III Study Evaluating the Efficacy and Safety of MK-0518, A Novel HIV-1 Integrase Inhibitor, In Patients with Triple-Class Resistant Virus. Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Feb. 25-28, 2007, Los Angeles, California. Abstract 105aLB.
    
    
17. Steigbigel R, Kumar P, et al. Results of BENCHMRK-2, A Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-Class Resistant Virus. Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Feb. 25-28, 2007, Los Angeles, California; Abstract 105bLB.